Endometrial cancer in women younger than 50 years: Clinicopathological features, treatment patterns and outcomes in a Moroccan cohort

Background: Endometrial cancer is the most frequent pelvic malignancy and occurs mainly in post‑menopausal women. Only a small proportion of cases are diagnosed in women under the age of 50, and data describing this population in North Africa are scarce. This study aimed to characterize the clinicopathological features, treatment modalities and outcomes of endometrial cancer in Moroccan women younger than 50 years. Methods: We performed a retrospective study of 40 women aged 33–50 years treated for endometrial cancer between 2018 and 2022 at the Hassan II University Hospital, Fees. Epidemiological, clinical and histopathological variables were extracted from standardized, anonymized forms. All patients underwent surgery; adjuvant treatments included external beam radiotherapy, high‑dose‑rate (HDR) vaginal brachytherapy and chemotherapy. Data were analyzed using SPSS v22.0; quantitative variables are summarized as means ± standard deviations and qualitative variables as numbers and percentages. Results: The mean age at diagnosis was 46 years (range 33–50). Forty‑five per cent of patients were pre‑menopausal and 52 % were nulliparous. Hypertension and diabetes were each present in one patient. Endometrioid adenocarcinoma accounted for 71.6 % of cases, whereas serous, clear‑cell, undifferentiated, mixed tumors and carcinosarcomas comprised 35.1 % of tumors. Most endometrioid tumors were grade 1 or 2. Over half of women presented with stage I disease (20 % stage IA, 37.5 % stage IB), while 25 % were stage III and 10 % stage IV. All patients underwent hysterectomy with bilateral sapling‑oophorectomy. In total, 54 % received adjuvant external beam radiotherapy (45–50 Gy) followed by HDR brachytherapy, 30 % received brachytherapy alone and 10 % received palliative chemotherapy. After a median follow‑up of 35 months, 63 % of patients remained disease‑free, 5 % experienced local recurrence, 15 % developed distant recurrence and 7.5 % showed progression despite adjuvant therapy. Conclusion: Endometrial cancer in Moroccan women younger than 50 years is predominantly endometrioid, low‑grade and early‑stage, mirroring global observations. Outcomes were favorable with multimodal therapy, and no unique clinicopathological features were identified compared with older patients. Nevertheless, the high proportion of nulliparous and pre‑menopausal women underscores the importance of counselling about fertility‑sparing options. For carefully selected patients with grade 1 endometrioid carcinoma limited to the endometrium, conservative management with high‑dose progestins or levonorgestrel‑releasing intrauterine devices may be considered, with definitive surgery advised once childbearing is complete.

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2025-09-30
DOI
https://doi.org/10.5281/zenodo.17748506
Primary Topic
Endometrial and Cervical Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Endometrial cancer in women younger than 50 years: Clinicopathological features, treatment patterns and outcomes in a Moroccan cohort

Zenodo (CERN European Organization for Nuclear Research)
Endometrial and Cervical Cancer Treatments
article

Endometrial cancer in women younger than 50 years: Clinicopathological features, treatment patterns and outcomes in a Moroccan cohort

article en

Abstract

Background: Endometrial cancer is the most frequent pelvic malignancy and occurs mainly in post‑menopausal women. Only a small proportion of cases are diagnosed in women under the age of 50, and data describing this population in North Africa are scarce. This study aimed to characterize the clinicopathological features, treatment modalities and outcomes of endometrial cancer in Moroccan women younger than 50 years. Methods: We performed a retrospective study of 40 women aged 33–50 years treated for endometrial cancer between 2018 and 2022 at the Hassan II University Hospital, Fees. Epidemiological, clinical and histopathological variables were extracted from standardized, anonymized forms. All patients underwent surgery; adjuvant treatments included external beam radiotherapy, high‑dose‑rate (HDR) vaginal brachytherapy and chemotherapy. Data were analyzed using SPSS v22.0; quantitative variables are summarized as means ± standard deviations and qualitative variables as numbers and percentages. Results: The mean age at diagnosis was 46 years (range 33–50). Forty‑five per cent of patients were pre‑menopausal and 52 % were nulliparous. Hypertension and diabetes were each present in one patient. Endometrioid adenocarcinoma accounted for 71.6 % of cases, whereas serous, clear‑cell, undifferentiated, mixed tumors and carcinosarcomas comprised 35.1 % of tumors. Most endometrioid tumors were grade 1 or 2. Over half of women presented with stage I disease (20 % stage IA, 37.5 % stage IB), while 25 % were stage III and 10 % stage IV. All patients underwent hysterectomy with bilateral sapling‑oophorectomy. In total, 54 % received adjuvant external beam radiotherapy (45–50 Gy) followed by HDR brachytherapy, 30 % received brachytherapy alone and 10 % received palliative chemotherapy. After a median follow‑up of 35 months, 63 % of patients remained disease‑free, 5 % experienced local recurrence, 15 % developed distant recurrence and 7.5 % showed progression despite adjuvant therapy. Conclusion: Endometrial cancer in Moroccan women younger than 50 years is predominantly endometrioid, low‑grade and early‑stage, mirroring global observations. Outcomes were favorable with multimodal therapy, and no unique clinicopathological features were identified compared with older patients. Nevertheless, the high proportion of nulliparous and pre‑menopausal women underscores the importance of counselling about fertility‑sparing options. For carefully selected patients with grade 1 endometrioid carcinoma limited to the endometrium, conservative management with high‑dose progestins or levonorgestrel‑releasing intrauterine devices may be considered, with definitive surgery advised once childbearing is complete.

Zenodo (CERN European Organization for Nuclear Research)
Centre Hospitalier Universitaire Hassan II (MA), Sidi Mohamed Ben Abdellah University (MA)
Good health and well-being
Openalex Percentile: Top 30%
Endometrial and Cervical Cancer Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.